Broadwood Partners acquires Staar Surgical shares worth $2.87 million

Broadwood Partners, L.P., a significant stakeholder in STAAR Surgical Co. (NASDAQ:STAA), recently increased its holdings in the company. According to a recent SEC filing, the firm purchased a total of 186,227 shares of STAAR Surgical, amounting to approximately $2.87 million. The transactions occurred over a span of three days, from April 8 to April 10, 2025, with purchase prices ranging from $14.70 to $15.99 per share. The purchases come as STAAR's stock has declined nearly 70% over the past year, with the current price of $15.57 sitting well below its 52-week high of $51.81.

The acquisitions were made through multiple transactions, with the largest single purchase involving 166,527 shares at an average price of $15.277 per share. Following these transactions, Broadwood Partners now holds 13,519,491 shares of STAAR Surgical. The purchases reflect Broadwood Partners' confidence in the ophthalmic goods company, which is headquartered in Monrovia, California. According to InvestingPro analysis, STAAR maintains strong financial health with a current ratio of 5.23 and more cash than debt on its balance sheet, though analysts have recently revised earnings expectations downward.

In other recent news, STAAR Surgical has been the focus of multiple analyst evaluations and leadership changes. The company recently reported fourth-quarter 2024 results that fell short of expectations, leading to adjustments in price targets by several analyst firms. Canaccord Genuity reduced its price target for STAAR Surgical to $17, maintaining a Hold rating, while Jefferies downgraded the stock and slashed its target to $18. Stifel also cut its price target to $20 but maintained a Buy rating, reflecting concerns over the Chinese market's impact on STAAR Surgical's performance.

The company announced significant executive changes, including the resignation of CFO Patrick Williams and the appointment of Deborah Andrews as Interim CFO. These leadership shifts, alongside the appointment of Warren Foust as President and COO, are part of STAAR Surgical's efforts to stabilize during a period of transition. Analysts from Piper Sandler and BTIG have maintained a Neutral rating on the stock, citing the need for more clarity on the company's recovery process and cost-saving strategies.

STAAR Surgical's reliance on the Chinese market has been a focal point, with analysts noting challenges in distributor inventory levels and macroeconomic conditions. Despite these hurdles, some analysts express cautious optimism about the company's long-term prospects, highlighting its differentiated technology and potential for market share gains. However, the lack of reiterated guidance for FY25 has left investors uncertain about the company's near-term outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.